0000899243-20-004907.txt : 20200218
0000899243-20-004907.hdr.sgml : 20200218
20200218165916
ACCESSION NUMBER: 0000899243-20-004907
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200214
FILED AS OF DATE: 20200218
DATE AS OF CHANGE: 20200218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND
CENTRAL INDEX KEY: 0001743774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 20626139
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS, INC.
STREET 2: 180 N. LASALLE STREET, SUITE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-14
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001743774
JOHNSON KENNETH ERLAND
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
0
1
0
0
See Remarks
Common Stock
2020-02-14
4
P
0
2410
4.15
A
6115
D
Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share.
Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
/s/ Beth Hecht, as Attorney-in-Fact
2020-02-18